Akebia Therapeutics, Inc.AKBA

時価総額

$4.4億

PER

腎疾患向け医薬品の新興企業。貧血治療薬AuryxiaとVafseoを展開。2024年にAuryxiaを約740万ドル分無償提供、同年12月に無償提供終了、従業員数181人（2024年12月31日時点）。米国・日本・欧州で展開。

	2014年 12月31日	2015年 12月31日	2016年 12月31日	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net loss	-37,034,039	-61	-136	-77	-144	-280	-383	-283	-93	-52	-69
Depreciation	49,363	0	-	-	-	-	-	-	-	2	1
Amortization of intangible asset	-	-	-	-	2	36	32	36	36	36	36
Bad debt expense	-	-	-	-	-	-	-	-	-	-	1
Fair Value Adjustment of Warrants	-	-	-	3	-	-	-	-	-	-	0
Noncash Interest Expense	-	-	-	-	0	1	2	1	2	-	13
Non-cash royalty revenue related to sale of future royalties	-	-	-	-	-	-	-	1	2	2	2
Noncash Research And Development Expense	-	-	-	-	-	-	-	-	9	1	-
Amortization of right-of-use assets	-	-	-	-	-	-	-	-	-	-	4
Non-cash write-off on termination of lease	-	-	-	-	-	-	-	-	-	1	-
Loss on extinguishment of debt	-	-	-	-	-	-	-	-	-	-	0
Inventory Write-down	-	-	-	-	-	7	20	16	30	-	4
Change in firm purchase commitments	-	-	-	-	-	-	-	-	-	2	2
Stock-based compensation expense	-	-	6	9	19	12	24	23	18	9	8
Increase (Decrease) in Derivative Liabilities	-	-	-	-	-	-	0	-1	-1	-1	-
Accounts receivable	-0	-	-	0	-33	22	-12	24	-12	-1	-4
Inventories	-	-	-	-	-0	29	-6	26	-20	3	28
Prepaid expenses and other current assets	1	1	-0	4	1	-11	8	19	-0	-12	-9
Other long-term assets	-	-	0	1	-1	-5	3	-6	6	1	-1
Accounts payable	-	0	-0	5	14	1	4	-12	2	-5	-1
Increase (Decrease) in Accrued Liabilities	-	5	21	22	55	-27	6	-25	-38	-10	-13
Lease liabilities	-	-	-	-	-	-	-	-	-	-5	-4
Deferred revenue	-	-	-	-	-67	-40	-32	2	5	-4	-
Other long-term liabilities	-	-	-	-	-	-	-	-12	2	-6	-6
Net cash used in operating activities	-	-	-	-	-97	-257	-110	-253	-73	-23	-41
Purchase of property and equipment	0	0	3	2	2	7	0	0	0	-	0
Net cash provided by (used in) investing activities	-	-	-	-	37	211	-40	40	-0	-	-0
Proceeds from Issuance of Debt	-	-	-	-	-	-	-	-	-	-	45
Payments of issuance costs related to BlackRock Credit Agreement	-	-	-	-	-	-	-	-	-	-	1
Proceeds From Issuance Of Common Stock Net Of Issuance Costs	-	83	67	115	95	26	209	88	7	7	42
Proceeds from Stock Plans	-	0	0	0	0	0	1	1	0	0	0
Proceeds from Stock Options Exercised	-	0	0	1	1	1	1	-	0	0	0
Repayment of term debt	-	-	-	-	-	-	-	-	-	-	37
Net cash (used in) provided by financing activities	-	-	-	-	97	89	232	134	15	-25	50
Increase (decrease) in cash, cash equivalents and restricted cash	-	-	-	-	36	43	81	-79	-59	-49	9
Deferred Unpaid Offering Costs	-	-	-	-	-	-	0	0	-	-	5
Cash paid for interest	-	-	-	-	-	-	-	10	7	6	5